الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 77 |  |  |
| | | from | 77 | | |
Abstract
Cyclosporine (CsA) emulsion 0.05% (Restasis®, Allergan, CA, USA) has been the only product to receive US FDA approval for the treatment of dry eye.
Cyclosporine A (CsA) is a cyclic undecapeptide produced by Tolypocladium inflattum Gams and other fungi imperfecti. This drug is now routinely used as an oral immunosuppressor for organ transplantation. It acts by selective inhibition of interleukin-2 release during the activation of T-cells and causes suppression of the cellmediated immune response.
The purpose of this study is to assess the effectiveness of cyclosporine-A ophthalmic emulsion in the treatment of dry eye.
The diagnosis of ocular surface disease is based on the symptoms and medical history which should include questions about topical and systemic medications used and possible exposure to risk factors.
The Management of ocular surface disorders requires good history and ophthalmological examination. The incorporation of a questionnaire may facilitate the evaluation of patients and aid in setting a diagnosis.
Examination of the eye was done with a special consideration to Tear break-up time , +ve corneal fluorescein staining to evaluate the signs of dryness in follow-up visits, in addition to the OSDI was used to evaluate the symptoms. Five visits were recorded in the form of base line visit (0 visit) 1st visit after 4weeks and 2nd visit after 8 weeks, 3rd visit after 12 weeks, 4th visit after 16weeks, of treatment by cyclosporine-A ophthalmic emulsion.
the IBM SPSS statistics version 22 was used to compare the efficacy tests scores & the safety test scores of the case and control groups before starting the treatment (day 0) and after finishing the treatment (day120).
Anumber of patients was used as our unit of analysis, patient were classified according to the status of the worst eye & P value was set at < 0.01.
Results showed improvement in subjective symptoms and quality of life (regarding OSDI p value <0.001), statistically significant improvement in the state of corneal and conjunctival epithelium (regarding fluorescein staining p value <0.001) and increased TBUT (regarding TBUT p value < 0.001) at 4 and 8 weeks after treatment initiation. However, in moderate and severe cases the cyclosporine –A ophthalmic emulsion approved more efficacy on signs and symptoms of dryness more than other tear substitute drops and the P-value was more significant.
The cyclosporine –A ophthalmic emulsion eye drops can provide a suitable alternate in the treatment of dry eye disease due to its reported efficacy on symptomatic improvement , promotion of corneal and conjunctival healing and increase in tear break-up timemore than other tear subs